Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo

Blood

Volumn 123, Issue 10, 2014, Pages 1564-1573

  Poli, Maura ^a   Asperti, Michela ^a   Naggi, Annamaria ^b   Campostrini, Natascia ^c   Girelli, Domenico ^c   Corbella, Michela ^c   Benzi, Marina ^b   Besson Fournier, Celine ^d   Coppin, Helene ^d   Maccarinelli, Federica ^a   Finazzi, Dario ^a   Arosio, Paolo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BONE MORPHOGENETIC PROTEIN 6; GLYCOL SPLIT HEPARIN; HEPCIDIN; LIPOPOLYSACCHARIDE; RO 68; RO 82; UNCLASSIFIED DRUG;

ACETYLATION; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTIHEPCIDIN ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; BRUCELLA ABORTUS; CELL STRAIN HEPG2; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; IRON KINETICS; LIVER CELL; LONG TERM CARE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SULFATION;

ANEMIA; ANIMALS; BONE MORPHOGENETIC PROTEIN 6; CELL LINE; DERMATAN SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPARIN; HEPCIDINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; IRON; LIPOPOLYSACCHARIDES; MICE; MICE, KNOCKOUT; PROMOTER REGIONS, GENETIC; SPLEEN; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84897504790     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-515221     Document Type: Article

References (58)

1. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004;117(3):285-297. (Pubitemid 38534536)
2. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142(1):24-38.
3. Arosio P, Levi S. Ferritin, iron homeostasis, and oxidative damage. Free Radic Biol Med. 2002;33(4):457-463. (Pubitemid 34874967)
4. Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 2001;33(10):940-959. (Pubitemid 32706687)
5. Casey JL, Hentze MW, Koeller DM, et al. Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. Science. 1988;240(4854):924-928.
6. Muckenthaler M, Gray NK, Hentze MW. IRP-1 binding to ferritin mRNA prevents the recruitment of the small ribosomal subunit by the cap-binding complex eIF4F. Mol Cell. 1998;2(3):383-388. (Pubitemid 128379278)
7. Hentze MW, Kühn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA. 1996;93(16):8175-8182. (Pubitemid 26269529)
8. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093. (Pubitemid 40007660)
9. Donovan A, Lima CA, Pinkus JL, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 2005;1(3):191-200. (Pubitemid 43960600)
10. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011;62:347-360.
11. MacKenzie EL, Iwasaki K, Tsuji Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008;10(6):997-1030. (Pubitemid 351451707)
12. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811-7819.
13. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434-1443.
14. Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program. 2011;2011:538-442.
15. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006;38(5):531-539.
16. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2005;2(6):399-409.
17. Samad TA, Rebbapragada A, Bell E, et al. DRAGON, a bone morphogenetic protein co-receptor. J Biol Chem. 2005;280(14):14122-14129. (Pubitemid 40517314)
18. Silvestri L, Guillem F, Pagani A, et al. Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia. Blood. 2009;113(22):5605-5608.
19. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41(4):478-481.
20. Roth MP, Coppin H. [BMP6: a key player in iron metabolism]. Med Sci (Paris). 2009;25(8-9):678-680.
21. Truksa J, Peng H, Lee P, Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci USA. 2006;103(27):10289-10293. (Pubitemid 44051159)
22. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109(1):353-358. (Pubitemid 46053077)
23. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006; 108(9):3204-3209.
24. Chung B, Verdier F, Matak P, Deschemin JC, Mayeux P, Vaulont S. Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone. FASEB J. 2010;24(6):2093-2103.
25. Zhen AW, Nguyen NH, Gibert Y, et al. The small molecule, genistein, increases hepcidin expression in human hepatocytes. Hepatology. 2013;58(4):1315-1325.
26. Besson-Fournier C, Latour C, Kautz L, et al. Induction of activin B by inflammatory stimuli upregulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood. 2012;120(2):431-439.
27. Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87(4):392-400.
28. Poli M, Girelli D, Campostrini N, et al. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood. 2011;117(3):997-1004.
29. Sakurai N. [Purification of bone morphogenetic protein and investigation of its effects on osteoblastic cell line UMR108]. Kokubyo Gakkai Zasshi. 1993;60(1):169-182.
30. Jiao X, Billings PC, O'Connell MP, Kaplan FS, Shore EM, Glaser DL. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem. 2007;282(2):1080-1086. (Pubitemid 47076568)
31. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem. 1996;237(1):295-302. (Pubitemid 26110301)
32. Kanzaki S, Takahashi T, Kanno T, et al. Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. J Cell Physiol. 2008;216(3):844-850.
33. Zhao B, Katagiri T, Toyoda H, et al. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem. 2006;281(32):23246-23253.
34. Takada T, Katagiri T, Ifuku M, et al. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem. 2003;278(44):43229-43235. (Pubitemid 37345942)
35. Brkljacic J, Pauk M, Erjavec I, et al. Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity. Int Orthop. 2013;37(3):529-541.
36. Casu B, Naggi A, Torri G. Chemical derivatization as a strategy to study structure-activity relationships of glycosaminoglycans. Semin Thromb Hemost. 2002;28(4):335-342. (Pubitemid 34971920)
37. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007;446(7139):1030-1037. (Pubitemid 46676065)
38. Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 2001;11(2):75-82. (Pubitemid 32144754)
39. Mulloy B, Rider CC. Cytokines and proteoglycans: an introductory overview. Biochem Soc Trans. 2006;34(Pt 3):409-413. (Pubitemid 43953999)
40. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood. 2002;99(4):1405-1410. (Pubitemid 34547098)
41. Ritchie JP, Ramani VC, Ren Y, et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res. 2011;17(6):1382-1393.
42. Presta M, Leali D, Stabile H, et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des. 2003;9(7):553-566. (Pubitemid 36221723)
43. Casu B, Naggi A, Torri G. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol. 2010;29(6):442-452.
44. Naggi A, Casu B, Perez M, et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem. 2005;280(13):12103-12113.
45. Conrad HE, Guo Y. Structural analysis of periodate-oxidized heparin. Adv Exp Med Biol. 1992;313:31-36.
46. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost. 2002;28(1):45-52. (Pubitemid 34194872)
47. Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics. 2010;73(3):527-536.
48. Dongiovanni P, Ruscica M, Rametta R, et al. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol. 2013;182(6):2254-2263.
49. Tjalsma H, Laarakkers CM, van Swelm RP, et al. Mass spectrometry analysis of hepcidin peptides in experimental mouse models. PLoS ONE. 2011;6(3):e16762.
50. Roetto A, Di Cunto F, Pellegrino RM, et al. Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues. Blood. 2010;115(16):3382-3389.
51. Cooke KS, Hinkle B, Salimi-Moosavi H, et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood. 2013;122(17):3054-3061.
52. Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010;115(17):3616-3624.
53. Malmström A, Bartolini B, Thelin MA, Pacheco B, Maccarana M. Iduronic acid in chondroitin/dermatan sulfate: biosynthesis and biological function. J Histochem Cytochem. 2012;60(12):916-925.
54. Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem. 2001;57:159-206. (Pubitemid 34121000)
55. Naggi A. Glycol-splitting as a device for modulating inhibition of growth factors and heparanase by heparin and heparin derivatives. In: Garg HG, Linhardt RJ, Hales CA, ed. Chemistry and Biology of Heparin and Heparan Sulfate. Oxford, United Kingdom: Elsevier Inc; 2005:461-482.
56. Casu B, Guerrini M, Guglieri S, et al. Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem. 2004;47(4):838-848. (Pubitemid 38176787)
57. Kragh M, Loechel F. Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis (review). [review] Int J Oncol. 2005; 27(4):1159-1167.
58. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117(7):1933-1939. (Pubitemid 47036327)